G
Giorgio Dini
Researcher at Istituto Giannina Gaslini
Publications - 201
Citations - 9124
Giorgio Dini is an academic researcher from Istituto Giannina Gaslini. The author has contributed to research in topics: Transplantation & Hematopoietic stem cell transplantation. The author has an hindex of 42, co-authored 201 publications receiving 8537 citations. Previous affiliations of Giorgio Dini include Boston Children's Hospital.
Papers
More filters
Journal ArticleDOI
Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study.
Katarina Le Blanc,Francesco Frassoni,Lynne M. Ball,Franco Locatelli,Helene Roelofs,Ian D. Lewis,Edoardo Lanino,Berit Sundberg,Maria Ester Bernardo,Mats Remberger,Giorgio Dini,R. Maarten Egeler,Andrea Bacigalupo,Willem E. Fibbe,Olle Ringdén +14 more
TL;DR: Infusion of mesenchymal stem cells expanded in vitro, irrespective of the donor, might be an effective therapy for patients with steroid-resistant, acute GVHD.
Journal ArticleDOI
Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe 2009.
Per Ljungman,Marco Bregni,Mats Brune,Jan J. Cornelissen,T. de Witte,Giorgio Dini,Herman Einsele,H. B. Gaspar,Alois Gratwohl,Jakob Passweg,C Peters,Vanderson Rocha,Riccardo Saccardi,Harry C. Schouten,Anna Sureda,André Tichelli,Andrea Velardi,Dietger Niederwieser +17 more
TL;DR: An updated report with revised tables and operating definitions is presented on the current practice of haematopoietic SCT for haem atological diseases, solid tumours and immune disorders in Europe.
Journal ArticleDOI
Risk score for outcome after allogeneic hematopoietic stem cell transplantation: a retrospective analysis.
Alois Gratwohl,Martin Stern,Ronald Brand,Jane F. Apperley,Helen Baldomero,Theo de Witte,Giorgio Dini,Vanderson Rocha,Jakob Passweg,Anna Sureda,André Tichelli,Dietger Niederwieser,Marrow Transplantation +12 more
TL;DR: The European Group for Blood and Marrow Transplantation risk score, previously established for chronic myeloid leukemia, could be used to predict outcome after allogeneic hematopoietic stem cell transplantation for hematological disease in general.
Journal ArticleDOI
Defibrotide for prophylaxis of hepatic veno-occlusive disease in paediatric haemopoietic stem-cell transplantation: an open-label, phase 3, randomised controlled trial
Selim Corbacioglu,Simone Cesaro,Maura Faraci,Dominique Valteau-Couanet,Bernd Gruhn,Attilio Rovelli,Jaap Jan Boelens,Annette Hewitt,Johanna Schrum,A. Schulz,Ingo Müller,Jerry Stein,Robert Wynn,Johann Greil,Karl Walter Sykora,Susanne Matthes-Martin,Monika Führer,Anne O'Meara,Jacek Toporski,Petr Sedlacek,Paul G. Schlegel,Karoline Ehlert,Anders Fasth,Jacek Winiarski,Johan Arvidson,Christine Mauz-Körholz,Hulya Ozsahin,André Schrauder,Peter Bader,Joseph M. Massaro,Ralph B. D'Agostino,Margaret Hoyle,Massimo Iacobelli,Klaus-Michael Debatin,Christina Peters,Giorgio Dini +35 more
TL;DR: Defibrotide prophylaxis seems to reduce incidence of veno-occlusive disease and is well tolerated, and could present a useful clinical option for this serious complication of HSCT.
Journal ArticleDOI
Stromal damage as consequence of high-dose chemo/radiotherapy in bone marrow transplant recipients.
Maria Galotto,G. Berisso,Laura Delfino,Marina Podestà,Laura Ottaggio,Sandro Dallorso,Carlo Dufour,Giovanni Battista Ferrara,Angelo Abbondandolo,Giorgio Dini,Andrea Bacigalupo,Ranieri Cancedda,Rodolfo Quarto +12 more
TL;DR: It is demonstrated that the marrow stromal microenvironment is seriously and irreversibly damaged after BMT, and donor cells do not contribute to reconstitute the marrow microenvironment, whose residual CFU-fs remain of host origin.